Irinotecan-induced immune thrombocytopenia

Am J Med Sci. 2014 Feb;347(2):167-9. doi: 10.1097/MAJ.0000000000000243.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, N.I.H., Extramural

MeSH terms

  • Antibodies, Monoclonal, Humanized / administration & dosage
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Antineoplastic Agents, Phytogenic / administration & dosage
  • Antineoplastic Agents, Phytogenic / adverse effects*
  • Antineoplastic Agents, Phytogenic / immunology
  • Antineoplastic Agents, Phytogenic / therapeutic use
  • Bevacizumab
  • Camptothecin / administration & dosage
  • Camptothecin / adverse effects
  • Camptothecin / analogs & derivatives*
  • Camptothecin / immunology
  • Camptothecin / therapeutic use
  • Colonic Neoplasms / drug therapy
  • Female
  • Fluorouracil / administration & dosage
  • Fluorouracil / therapeutic use
  • Humans
  • Irinotecan
  • Leucovorin / administration & dosage
  • Leucovorin / therapeutic use
  • Middle Aged
  • Platelet Count
  • Thrombocytopenia / chemically induced*
  • Thrombocytopenia / immunology

Substances

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents, Phytogenic
  • Bevacizumab
  • Irinotecan
  • Leucovorin
  • Fluorouracil
  • Camptothecin